Macula Risk is a prognostic DNA test intended for patients who have a diagnosis of early or intermediate AMD. Using the complete combination of AMD genes, and smoking history, Macula Risk identifies those most likely to progress from early or intermediate Dry AMD to advanced AMD with vision loss. Most insurance providers, including Medicare, reimburse the Macula Risk test.
Macula Risk uses a simple cheek swab to take a sample of the patient’s DNA. This sample is sent to a certified DNA testing laboratory for analysis, and your eye care provider will have your results back from the laboratory in 3-4 weeks. For patients with early or intermediate signs of AMD, Macula Risk identifies the 20% (1 in every 5) who are at the highest risk of vision loss due to AMD. Identifying these patients early will allow the eye care provider to implement a disease management strategy that best suits individual patient needs and is focused on sight preservation.
Regardless of family history, if you have early signs of AMD, then you should speak to your eye care provider to determine if measures such as more regular eye examinations and testing with Macula Risk are appropriate for you. Macula Risk genetic testing is only available through an eye care professional.